Skip to content
DataLookout
Menu

NCT06397573

Ablative Stereotactic MR-Guided Adaptive Reirradiation

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 21 words Show 5 more changesShow less
    • Trial completed
    • Final enrollment: 11 participants (planned 10)
    • Study completion date changed from estimate of Jun 2027 to Aug 20, 2026
    • Secondary endpoints: details revised at 3 of 4 entries
    • Publications: details revised at 7 of 7 entries
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Jun 2027 to Aug 2026
    • Site details revised
    • Collaborators shortened, about 3 words
    v5
  3. Notable Eligibility criteria shortened, about 9 wordsv4
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 2024 to Jun 5, 2024
    • Site details revised
    v3
  5. Notable Phase: Phase 1 to Not applicable
    • Study title shortened, about 4 words
    v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Grade 3 or higher acute toxicity
Timeframe: 1 year
Grade 5 toxicity
Timeframe: 1 year

Secondary (4)

Freedom from local progression (FFLP)
Overall survival (OS)
Grade 3 or higher late toxicity
Quality of life (QOL)

Arms and interventions

Ablative ReirradiationExperimental

Radiation: Reirradiation

Sites

1 site in 1 country

  • Miami Cancer Institute at Baptist Health South FloridaMiami, Florida, United States